↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of agomelatine and its potential in the treatment of generalized anxiety disorder

Overview of attention for article published in Neuropsychiatric Disease and Treatment, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
6 tweeters
patent
3 patents
facebook
2 Facebook pages

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
31 Mendeley
Title
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
Published in
Neuropsychiatric Disease and Treatment, May 2015
DOI 10.2147/ndt.s67470
Pubmed ID
Authors

Michelle Levitan, Marcelo Papelbaum, Antonio E Nardi

Abstract

Although many generalized anxiety disorder (GAD) patients respond to the available pharmacological treatments, nearly half of them do not present the expected results. Besides, the side effects associated to some drugs have a negative impact on treatment adherence. Therefore, the aim of this review was to report the clinical profile of agomelatine, a selective melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2c receptor antagonist activities, as a potential pharmacological option in the treatment of GAD. We performed a literature review regarding studies that evaluated the use of agomelatine in GAD treatment. Two short-term, double-blinded studies and one prevention-treatment trial evaluated the efficacy of agomelatine in the treatment of GAD. Agomelatine was associated with higher rates of clinical response and remission, when compared to placebo. In addition, the long-term use of agomelatine decreased the risk of relapse of anxiety symptoms, even for the severely ill patients. Besides, the tolerability was satisfactory with the absence of discontinuation symptoms, as observed in previous studies. The efficacy and tolerability profiles of agomelatine in the treatment of GAD were good. However, the scarce number of trials, the small sample sizes, and the use of patients without any comorbid conditions were some limitations that impaired the generalization of the results in the general population. Nevertheless, agomelatine is an attractive off-label option in the treatment of GAD that needs more conclusive evidences to establish its role in future guidelines.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 3%
Unknown 30 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 19%
Researcher 6 19%
Student > Bachelor 3 10%
Student > Doctoral Student 2 6%
Professor 2 6%
Other 6 19%
Unknown 6 19%
Readers by discipline Count As %
Medicine and Dentistry 13 42%
Pharmacology, Toxicology and Pharmaceutical Science 5 16%
Neuroscience 2 6%
Agricultural and Biological Sciences 1 3%
Social Sciences 1 3%
Other 2 6%
Unknown 7 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2020.
All research outputs
#3,318,027
of 16,975,484 outputs
Outputs from Neuropsychiatric Disease and Treatment
#500
of 2,634 outputs
Outputs of similar age
#50,838
of 235,225 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#9
of 39 outputs
Altmetric has tracked 16,975,484 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,634 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,225 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.